SCHEMBL10169246

SCHEMBL10169246

CCCCCCCCCCCCCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(C)=O)C(C)C)[C@@H](C)O

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 1/20 0.55
▸ GCGR P47871 1/20 0.55
▸ GIPR P48546 1/20 0.55
▸ TFPI P10646 1/20 0.55
▸ IL23R Q5VWK5 5/20 0.55
▸ OPRL1 P41146 5/20 0.52
▸ KISS1R Q969F8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169057 0.97 GLP1R (0.52) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169247 0.97 GLP1R (0.52) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169225 0.97 GLP1R (0.52) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169260 0.97 GLP1R (0.52) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10168306 0.97 GLP1R (0.52) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10168556 0.95 GLP1R (0.54) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169206 0.95 GLP1R (0.55) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10168561 0.95 GLP1R (0.55) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169233 0.95 GLP1R (0.55) GLP1RGCGRGIPRTFPIIL23R
SCHEMBL10169046 0.95 GLP1R (0.55) GLP1RGCGRGIPRTFPIIL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028888-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. 2012-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028888-A1 APJ RECEPTOR COMPOUNDS APLNR, AP1G1, AP2B1 GLP1R 53/4885GCGR 74/4885GIPR 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback